Compare
Evommune, Inc. vs Tonix Pharmaceuticals Holding Corp. vs Palatin Technologies Inc vs Emmaus Life Sciences, Inc.
| Latest fiscal year | Evommune, Inc. EVMN | Tonix Pharmaceuticals Holding Corp. TNXP | Palatin Technologies Inc PTN | Emmaus Life Sciences, Inc. EMMA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $13.00M | $13.11M | $13.19M | $12.45M |
| Revenue growth (YoY) | +85.7% | +29.8% | n/a | -25.2% |
| Gross margin | n/a | 49.3% (computed) | n/a | 93.1% |
| Operating margin | -623.6% | -959.1% | -65.7% | 1.9% |
| Net margin | -529.8% | -946.2% | -63.5% | -60.2% |
| Net income | -$68.87M | -$124.02M | -$8.38M | -$7.49M |
| EPS (Diluted) | -$11.22 | -$14.57 | -$2.96 | -$0.12 |
| Operating cash flow | -$76.44M | -$99.84M | -$13.53M | -$11.0K |
| Free cash flow | -$76.68M | -$103.21M | -$13.58M | -$12.0K |
| Cash & equivalents | $44.06M | $207.64M | $7.49M | $2.13M |
| Total assets | $224.95M | $277.17M | $8.52M | $21.44M |
| Total liabilities | $19.38M | $32.02M | $1.84M | $85.04M |
| Shareholders' equity | $205.57M | $245.15M | $6.69M | -$63.61M |
| Return on year-end equity | -33.5% | -50.6% | -125.3% | n/a |
| Shares outstanding | 31.52M | 12.79M | 1.78M | 70.19M |
Revenue, most recent five fiscal years
| Fiscal year | Evommune, Inc. | Tonix Pharmaceuticals Holding Corp. | Palatin Technologies Inc | Emmaus Life Sciences, Inc. |
|---|---|---|---|---|
| Latest | $13.00M Ended 2025-12-31 | $13.11M Ended 2025-12-31 | $13.19M Ended 2026-06-30 | $12.45M Ended 2025-12-31 |
| 1 year earlier | $7.00M Ended 2024-12-31 | $10.09M Ended 2024-12-31 | n/a | $16.65M Ended 2024-12-31 |
| 2 years earlier | n/a | $7.77M Ended 2023-12-31 | n/a | $29.60M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $18.39M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $20.61M Ended 2021-12-31 |